The most fundamental change is that the revised models apply to health services in England, Northern Ireland, Scotland and Wales and replace the 2011 national versions. Therefore, a single standard contract for commercial clinical trials throughout Britain will be possible, which will not allow the same study to be managed unnecessarily throughout Britain. ABPI commented that “the new mCTA enjoys broad support for life sciences leaders within government across Britain for the potential it has to accelerate innovative research and development.” There are several different model conventions and you should use the one that best suits your type of study and sponsorship agreements. For more information, visit the IRAS website. The original MCTA was published in 2003 and revised in 2006 and 2011.